Yahoo Finance

Windtree Therapeutics (WINT) announced that the Company has completed national phase filings of patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. “Windtree continues to prepare for the potential of istaroxime in treating cardiogenic shock patients by expanding and strengthening our patent estate,” said Craig Fraser, Chairman and Chief Executive Officer of Windtree. “Unique aspects of istaroxime are utilized in our strategy for intellectual property and positive clinical development has helped bring these aspects to light.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on WINT:

• Windtree Therapeutics announces issuance of istaroxime patent for Japan

• Windtree announces trial design of Phase 2b study of Istaroxime published

• Windtree Therapeutics Appoints New Senior VP and CFO

• Windtree Therapeutics to hold a virtual investor day

• Windtree Therapeutics Updates Investor Presentation Materials